The DOI matches its Crossref record; 65 of the 65 references it cites were found in a registry or an index.
Impaired Glutamate Uptake in the R6 Huntington's Disease Transgenic Mice
Open accessAbstract
Huntington's disease (HD) is a late-onset neurodegenerative disease for which the mutation is CAG/polyglutamine repeat expansion. The R6 mouse lines expressing the HD mutation develop a movement disorder that is preceded by the formation of neuronal polyglutamine aggregates. The phenotype is likely caused by a widespread neuronal dysfunction, whereas neuronal cell death occurs late and is very selective. We show that a decreased mRNA level of the major astroglial glutamate transporter (GLT1) in the striatum and cortex of these mice is accompanied by a concomitant decrease in glutamate uptake. In contrast, the expression of the glutamate transporters, GLAST and EAAC1, remain unchanged. The mRNA level of the astroglial enzyme glutamine synthetase is also decreased. These changes in expression occur prior to any evidence of neurodegeneration and suggest that a defect in astrocytic glutamate uptake may contribute to the phenotype and neuronal cell death in HD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
MACDONALD, M. (1993) · Cell · doi:10.1016/0092-8674(93)90585-e · Cited by 8,366
Mangiarini, L., Sathasivam, K., Seller, M., Cozens, B., Harper, A., Hetherington, C., Lawton, M., Trottier, Y., Lehrach, H., Davies, S. W., et al. (1996) · Cell · doi:10.1016/s0092-8674(00)81369-0 · Cited by 3,073
Self-citationAggregation of Huntingtin in Neuronal Intranuclear Inclusions and Dystrophic Neurites in Brain
DiFiglia, M., Sapp, E., Chase, K. O., Davies, S. W., Bates, G. P., Vonsattel, J. P., & Aronin, N. (1997) · Science · doi:10.1126/science.277.5334.1990 · Cited by 2,439
Self-citationNeuropathological Classification of Huntingtonʼs Disease
VONSATTEL, J.-P., MYERS, R. H., STEVENS, T. J., FERRANTE, R. J., BIRD, E. D., & RICHARDSON, E. P. (1985) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-198511000-00003 · Cited by 2,227
Davies, S. W., Turmaine, M., Cozens, B. A., DiFiglia, M., Sharp, A. H., Ross, C. A., Scherzinger, E., Wanker, E. E., Mangiarini, L., & Bates, G. P. (1997) · Cell · doi:10.1016/s0092-8674(00)80513-9 · Cited by 2,181
Self-citationEpilepsy and Exacerbation of Brain Injury in Mice Lacking the Glutamate Transporter GLT-1
Tanaka, K., Watase, K., Manabe, T., Yamada, K., Watanabe, M., Takahashi, K., Iwama, H., Nishikawa, T., Ichihara, N., Kikuchi, T., et al. (1997) · Science · doi:10.1126/science.276.5319.1699 · Cited by 1,752
Scherzinger, E., Lurz, R., Turmaine, M., Mangiarini, L., Hollenbach, B., Hasenbank, R., Bates, G. P., Davies, S. W., Lehrach, H., & Wanker, E. E. (1997) · Cell · doi:10.1016/s0092-8674(00)80514-0 · Cited by 1,291 · cited 1×
“The only molecular property thus far shown to correlate with this CAG repeat threshold is an increase in the rate at which exon 1 huntingtin can form amyloid fibrils in vitro (Scherzinger et al., 1997, 1999).”
BackgroundSelf-citationCloning and expression of a rat brain L-glutamate transporter
Pines, G., Danbolt, N. C., Bjørås, M., Zhang, Y., Bendahan, A., Eide, L., Koepsell, H., Storm-Mathisen, J., Seeberg, E., & Kanner, B. I. (1992) · Nature · doi:10.1038/360464a0 · Cited by 1,232
Storck, T., Schulte, S., Hofmann, K., & Stoffel, W. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.22.10955 · Cited by 1,183
Functional comparisons of three glutamate transporter subtypes cloned from human motor cortex
Arriza, J., Fairman, W., Wadiche, J., Murdoch, G., Kavanaugh, M., & Amara, S. (1994) · The Journal of Neuroscience · doi:10.1523/jneurosci.14-09-05559.1994 · Cited by 993
Cited by
Molecular Mechanisms and Potential Therapeutical Targets in Huntington's Disease
Zuccato, C., Valenza, M., & Cattaneo, E. (2010) · Physiological Reviews · doi:10.1152/physrev.00041.2009 · Cited by 848
Mechanisms of Disease: astrocytes in neurodegenerative disease
Maragakis, N. J., & Rothstein, J. D. (2006) · Nature Clinical Practice Neurology · doi:10.1038/ncpneuro0355 · Cited by 812
Astrocytes: a central element in neurological diseases
Pekny, M., Pekna, M., Messing, A., Steinhäuser, C., Lee, J.-M., Parpura, V., Hol, E. M., Sofroniew, M. V., & Verkhratsky, A. (2016) · Acta Neuropathologica · doi:10.1007/s00401-015-1513-1 · Cited by 755
Chronic Glutamate Toxicity in Neurodegenerative Diseases—What is the Evidence?
Lewerenz, J., & Maher, P. (2015) · Frontiers in Neuroscience · doi:10.3389/fnins.2015.00469 · Cited by 718
Sheldon, A. L., & Robinson, M. B. (2007) · Neurochemistry International · doi:10.1016/j.neuint.2007.03.012 · Cited by 594
Molecular Targets of Cannabidiol in Neurological Disorders
Ibeas Bih, C., Chen, T., Nunn, A. V. W., Bazelot, M., Dallas, M., & Whalley, B. J. (2015) · Neurotherapeutics · doi:10.1007/s13311-015-0377-3 · Cited by 578
Extrasynaptic NMDA Receptor Involvement in Central Nervous System Disorders
Parsons, M. P., & Raymond, L. A. (2014) · Neuron · doi:10.1016/j.neuron.2014.03.030 · Cited by 553
Kynurenine 3-Monooxygenase Inhibition in Blood Ameliorates Neurodegeneration
Zwilling, D., Huang, S.-Y., Sathyasaikumar, K. V., Notarangelo, F. M., Guidetti, P., Wu, H.-Q., Lee, J., Truong, J., Andrews-Zwilling, Y., Hsieh, E. W., et al. (2011) · Cell · doi:10.1016/j.cell.2011.05.020 · Cited by 515
Huntington’s Disease: Mechanisms of Pathogenesis and Therapeutic Strategies
Jimenez-Sanchez, M., Licitra, F., Underwood, B. R., & Rubinsztein, D. C. (2017) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a024240 · Cited by 507
Expression of mutant huntingtin in glial cells contributes to neuronal excitotoxicity
Shin, J.-Y., Fang, Z.-H., Yu, Z.-X., Wang, C.-E., Li, S.-H., & Li, X.-J. (2005) · The Journal of Cell Biology · doi:10.1083/jcb.200508072 · Cited by 477
Mechanisms of neurodegeneration in Huntington’s disease
Gil, J. M., & Rego, A. C. (2008) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2008.06310.x · Cited by 471
Elusive roles for reactive astrocytes in neurodegenerative diseases
Ben Haim, L., Carrillo-de Sauvage, M.-A., Ceyzériat, K., & Escartin, C. (2015) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2015.00278 · Cited by 453
Glial cells as intrinsic components of non-cell-autonomous neurodegenerative disease
Lobsiger, C. S., & Cleveland, D. W. (2007) · Nature Neuroscience · doi:10.1038/nn1988 · Cited by 441
Astrocytes in human central nervous system diseases: a frontier for new therapies
Verkhratsky, A., Butt, A., Li, B., Illes, P., Zorec, R., Semyanov, A., Tang, Y., & Sofroniew, M. V. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01628-9 · Cited by 428
Astrocytes in Neurodegenerative Disease: Table 1.
Phatnani, H., & Maniatis, T. (2015) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a020628 · Cited by 420
N-Methyl-d-aspartate (NMDA) receptor function and excitotoxicity in Huntington's disease
FAN, M., & RAYMOND, L. (2007) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2006.11.003 · Cited by 413
Huntington's disease: from pathology and genetics to potential therapies
Imarisio, S., Carmichael, J., Korolchuk, V., Chen, C.-W., Saiki, S., Rose, C., Krishna, G., Davies, J. E., Ttofi, E., Underwood, B. R., et al. (2008) · Biochemical Journal · doi:10.1042/bj20071619 · Cited by 409
Neuroinflammation and regulation of glial glutamate uptake in neurological disorders
Tilleux, S., & Hermans, E. (2007) · Journal of Neuroscience Research · doi:10.1002/jnr.21325 · Cited by 381
Transporters for L‐glutamate: An update on their molecular pharmacology and pathological involvement
Beart, P. M., & O'Shea, R. D. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0706949 · Cited by 377
Glutamate metabolism and recycling at the excitatory synapse in health and neurodegeneration
Andersen, J. V., Markussen, K. H., Jakobsen, E., Schousboe, A., Waagepetersen, H. S., Rosenberg, P. A., & Aldana, B. I. (2021) · Neuropharmacology · doi:10.1016/j.neuropharm.2021.108719 · Cited by 371
Expression of mutant huntingtin in mouse brain astrocytes causes age-dependent neurological symptoms
Bradford, J., Shin, J.-Y., Roberts, M., Wang, C.-E., Li, X.-J., & Li, S. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0911503106 · Cited by 362
Glutamate transporters: animal models to neurologic disease
Maragakis, N. J., & Rothstein, J. D. (2004) · Neurobiology of Disease · doi:10.1016/j.nbd.2003.12.007 · Cited by 352
Raymond, L. A., André, V. M., Cepeda, C., Gladding, C. M., Milnerwood, A. J., & Levine, M. S. (2011) · Neuroscience · doi:10.1016/j.neuroscience.2011.08.052 · Cited by 325
Cepeda, C., Hurst, R. S., Calvert, C. R., Hernández-Echeagaray, E., Nguyen, O. K., Jocoy, E., Christian, L. J., Ariano, M. A., & Levine, M. S. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-03-00961.2003 · Cited by 321
Early synaptic pathophysiology in neurodegeneration: insights from Huntington's disease
Milnerwood, A. J., & Raymond, L. A. (2010) · Trends in Neurosciences · doi:10.1016/j.tins.2010.08.002 · Cited by 312
The corticostriatal pathway in Huntington's disease
CEPEDA, C., WU, N., ANDRE, V, CUMMINGS, D., & LEVINE, M. (2007) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2006.11.001 · Cited by 310
Miller, B. R., Dorner, J. L., Shou, M., Sari, Y., Barton, S. J., Sengelaub, D. R., Kennedy, R. T., & Rebec, G. V. (2008) · Neuroscience · doi:10.1016/j.neuroscience.2008.02.004 · Cited by 280
“On post-treatment days 1 and 7, saline-treated R6/2s spent less time climbing than WTs (P 0.001), but with ceftriaxone treatment, climbing time was comparable in R6/2 and WT mice on both post-treatment days and significantly more than saline-treated R6/2 mice on post-treatment day 1 (P 0.05) (Fig.”
BackgroundResultInfluentialThe choreography of neuroinflammation in Huntington's disease
Crotti, A., & Glass, C. K. (2015) · Trends in Immunology · doi:10.1016/j.it.2015.04.007 · Cited by 276
Orexin loss in Huntington's disease
Petersén, Å., Gil, J., Maat-Schieman, M. L. C., Björkqvist, M., Tanila, H., Araújo, I. M., Smith, R., Popovic, N., Wierup, N., Norlén, P., et al. (2005) · Human Molecular Genetics · doi:10.1093/hmg/ddi004 · Cited by 271
Transcriptional signatures in Huntington's disease
Cha, J.-H. J. (2007) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2007.03.004 · Cited by 268
Genetics and Neuropathology of Huntington's Disease
Reiner, A., Dragatsis, I., & Dietrich, P. (2011) · International Review of Neurobiology · doi:10.1016/b978-0-12-381328-2.00014-6 · Cited by 261
Neostriatal and cortical quinolinate levels are increased in early grade Huntington's disease
GUIDETTI, P., LUTHICARTER, R., AUGOOD, S., & SCHWARCZ, R. (2004) · Neurobiology of Disease · doi:10.1016/j.nbd.2004.07.006 · Cited by 260
Surface diffusion of astrocytic glutamate transporters shapes synaptic transmission
Murphy-Royal, C., Dupuis, J. P., Varela, J. A., Panatier, A., Pinson, B., Baufreton, J., Groc, L., & Oliet, S. H. R. (2015) · Nature Neuroscience · doi:10.1038/nn.3901 · Cited by 252
Jiang, R., Diaz-Castro, B., Looger, L. L., & Khakh, B. S. (2016) · The Journal of Neuroscience · doi:10.1523/jneurosci.3693-15.2016 · Cited by 237
Presynaptic regulation of astroglial excitatory neurotransmitter transporter GLT1
Yang, Y., Gozen, O., Watkins, A., Lorenzini, I., Lepore, A., Gao, Y., Vidensky, S., Brennan, J., Poulsen, D., Won Park, J., et al. (2009) · Neuron · doi:10.1016/j.neuron.2009.02.010 · Cited by 237
Astrocyte-immune cell interactions in physiology and pathology
Han, R. T., Kim, R. D., Molofsky, A. V., & Liddelow, S. A. (2021) · Immunity · doi:10.1016/j.immuni.2021.01.013 · Cited by 223
Zou, J., Wang, Y.-X., Dou, F.-F., Lü, H.-Z., Ma, Z.-W., Lu, P.-H., & Xu, X.-M. (2010) · Neurochemistry International · doi:10.1016/j.neuint.2009.12.021 · Cited by 181
“A decline in GS activity and/or expression has been reported in these disorders (Oliver et al., 1990; Grosche et al., 1995; Robinson, 2000; Lievens et al., 2001).”
Excitatory Amino Acid Transporters in Physiology and Disorders of the Central Nervous System
Malik, A. R., & Willnow, T. E. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20225671 · Cited by 170
Synaptic dysfunction in Huntington's disease: a new perspective
Smith, R., Brundin, P., & Li, J.-Y. (2005) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-005-5084-5 · Cited by 166
Glia in the pathogenesis of neurodegenerative diseases
Verkhratsky, A., Parpura, V., Pekna, M., Pekny, M., & Sofroniew, M. (2014) · Biochemical Society Transactions · doi:10.1042/bst20140107 · Cited by 141
The contribution of glial cells to Huntington's disease pathogenesis
Wilton, D. K., & Stevens, B. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.104963 · Cited by 112
“this may underlie the increase in evoked calcium signaling in astrocytes (Arzberger et al., 1997; Bradford et al., 2009; Jiang et al., 2016; Lievens et al., 2001) (Table 2).”
BackgroundThe Relationship Between Glutamate Dynamics and Activity-Dependent Synaptic Plasticity
Barnes, J. R., Mukherjee, B., Rogers, B. C., Nafar, F., Gosse, M., & Parsons, M. P. (2020) · The Journal of Neuroscience · doi:10.1523/jneurosci.1655-19.2020 · Cited by 89
Astrocytes and microglia in neurodegenerative diseases: Lessons from human in vitro models
Franklin, H., Clarke, B. E., & Patani, R. (2021) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2020.101973 · Cited by 66
On astrocyte-neuron interactions: broad insights from the striatum
Khakh, B. S. (2025) · Neuron · doi:10.1016/j.neuron.2025.08.009 · Cited by 23
Metadata
- Authors
- Liévens, J.-C., Woodman, B., Mahal, A., Spasic-Boscovic, O., Samuel, D., Kerkerian-Le Goff, L., & Bates, G. P.
- Venue
- Neurobiology of Disease
- Publisher
- Elsevier BV
- Published
- 2001-10
- Volume
- 8
- Issue
- 5
- Pages
- 807-821
- ISSN
- 0969-9961 (ISSN-L)
- OpenAlex
- W1965044068
- Cited by
- 313
- References
- 65
- FWCI
- 2.78
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.